# 510(k) Summary of Safety and Effectiveness for the

# ADVIA $\textsuperscript { \textregistered }$ 1650 Chemistry Glucose Hexokinase_3 (GLUH_3) method

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

A. 510(k) Number: _k101854   
B. Date of Preparation: July 26, 2010   
C. Proprietary and Established Names: ADVIA $\textsuperscript { \textregistered }$ 1650 Chemistry Glucose Hexokinase_3 (GLUH_3) reagent   
D. Applicant: Siemens Healthcare Diagnostics Inc., 511 Benedict Ave, Tarrytown, NY 10591 Kira Gordon, Sr. Regulatory Affairs Specialist Office: (914) 524-2996 Fax: (914) 524-2500

# E. Regulatory Information:

ADVIA 1650 Chemistry Glucose Hexokinase_3 Reagent

1. Regulation section: 21 CFR $\ S$ 862.1345 Glucose test system.

2. Classification: Class II

3. Product Code: CFR, Hexokinase, Glucose

4.Panel: Clinical Chemistry

# F. Predicate Device:

ADVIA 1650 Chemistry Glucose Hexokinase_ 3 reagent is substantially equivalent to the ADVIA Chemistry Glucose Hexokinase II reagent cleared under k042015

# G. Device Description:

The ADVIA 1650 Chemistry Glucose Hexokinase_3 (GLUH_3) method uses a twocomponent reagent. Sample is added to Reagent 1, which contains the buffer, ATP, and NAD. Absorbance readings of the sample in Reagent 1 are taken and are used to correct for interfering substances in the sample. Reagent 2 is added, which initiates the conversion of glucose and the development of absorbance at $3 4 0 / 4 1 0 \ \mathrm { n m }$ The difference between the absorbance in Reagent 1 and Reagent 2 is proportional to the glucose concentration.

# H. Intended Use:

For in vitro diagnostic use in the quantitative detcrmination of glucose in human serum, plasma, urine and CSF on the ADVIA 1650 Chemistry system. Such measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and insulin overdose

# I. Substantial Equivalence Information:

The new device (Glucose Hexokinase_3 reagent) and the predicate device (Glucose Hexokinase II reagent) were compared. A comparison of the important features between the new device and the predicate device is provided in the following table:

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Glucose</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For in vitro diagnostic use in thequantitative determination of glucose inhuman serum, plasma, urine and CSF onthe ADVIA 1650 Chemistry system.Such measurements are used in thediagnosis and treatment of carbohydratemetabolism disorders including diabetesmellitus, neonatal hypoglycemia,idiopathic hypoglycemia, and insulinoverdose</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">human serum, plasma, urine and CSF(plasma  Li Heparin and K EDTA)</td><td colspan="1" rowspan="1">human serum, plasma, urine and CSF(plasma - Li Heparin)</td></tr><tr><td colspan="1" rowspan="1">Instrument tobe used</td><td colspan="1" rowspan="1">ADVIA 1650 Chemistry</td><td colspan="1" rowspan="1">ADVIA 1650 Chemistry</td></tr><tr><td colspan="1" rowspan="1">MethodPrinciple</td><td colspan="1" rowspan="1">based on the method by Slein usinghexokinase and glucose-6-phosphatedehydrogenase enzymes.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Siemens Healthcare DiagnosticsChemistry Calibrator REF 09784096</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reportablerange</td><td colspan="1" rowspan="1">4 -700 mg/dL</td><td colspan="1" rowspan="1">0 -700 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Traccability</td><td colspan="1" rowspan="1">Standard reference material 965a fromNIST</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Concentrate</td></tr><tr><td colspan="1" rowspan="1">Reagents</td><td colspan="1" rowspan="1">Two: R1 and R2</td><td colspan="1" rowspan="1">Threc: R1, R2 and R2 mix</td></tr><tr><td colspan="1" rowspan="1">InterferingSubstances *</td><td colspan="1" rowspan="1">Bilirubin-NSI to 30 mg/dL at glucoselevel of 54 mg/dLHemoglobin-NSI up to 1000 mg/dL atglucose level of 52 mg/dLLipemia (Intralipid)NSI to 1000 mg/dLat glucose level of 53 mg/dL :</td><td colspan="1" rowspan="1">Bilirubin-NSI to 25 mg/dL at glucoselevel of 80 mg/dLHemoglobinâ€”NSI up to 500 mg/dL atglucose level of 80 mg/dLLipemia (Intralipid)NSI to 500 mg/dLat glucose level of 80 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Precision(total)</td><td colspan="1" rowspan="1">0.8% at 87 mg/dL (serum)0.7% at 297 mg/dL (serum)1.1% at 49 mg/dL (urine)1.9% at 301 mg/dL (urinc)1.0% at 56 mg/dL (CSF)0.8% at 97 mg/dL (CSF)</td><td colspan="1" rowspan="1">2.2% at 74.7 mg/dL (serum)2.0% at 247.6 mg/dL (serum)4.1% at 45.8 mg/dL (urine)3.6% at 266.7 mg/dL (urine)3.1% at 36.9 mg/dL (CSF)2.7% at 60.2 mg/dL (CSF)</td></tr><tr><td colspan="1" rowspan="1">Accuracy /Correlation</td><td colspan="1" rowspan="1">Serum:Y = 1.001x + 0.3; N=99 r=1.000 (vs.ADVIA 1650 (ADVIA GLUH reagent)Plasma (Li-Heparin):Y = 1.001x + 0.2, N=88; r=1.000Plasma (K-EDTA)Y = 1.002x - 0.0, N=87; r=1.000CSF:Y = 1.005x - 0.1, N=113; r=1.000Urine:Y = 0.989x - 0.3, N=51; r=1.000</td><td colspan="1" rowspan="1">Serum:Y = 1.02x - 1.84; N=194 r=0.998 (vs.ADVIA 1650 (ADVIA glucose-singlereagent formulation))Plasma (Li Heparin):Y = 1.00x - 0.09, N=35; r=1.000CSF:Y = 1.03x - 1.25, N=55; r=0.987Urine:Y = 0.97x - 7.44, N=99; r=0.999</td></tr></table>

E ${ } ^ { * } \mathrm { N S I } { } ; = \mathrm { N o }$ Significant Interference. A percentage effect $> 1 0 \%$ is considered significant interference.

# J. Conclusion:

Comparative testing of the ADVIA 1650 Chemistry Glucose Hexokinase_3 reagent demonstrates substantially equivalent performance to the ADVIA Chemistry Glucose Hexokinase 1I reagent cleared under K042015.

Siemens Healthcare Diagnostics, Inc. c/o Kira Gordon   
Senior Regulatory Affairs Specialist 511 Benedict Avenue,   
Tarrytown, NY, 10591, USA   
Re: k101854   
Trade/Device Name: ADVIA Chemistry Glucose Hexokinase (GLUH_3) Reagent   
Regulation Number: 21 CFR 862.1345   
Regulation Name: Glucose Test System   
Regulatory Class: Class II   
Product Code: CFR   
Dated: February 23, 2011   
Received: February 24, 2011

Dear Ms. Gordon

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

I your device is classified (see above) into either class II (Special Controls) or classIII (PMA), it xit found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply w c  c  o  t  t 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Als0, please note the regulation entitled, "Misbranding by reference to premarket notification" (1 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division f Postmarket Surveilance at 30179-70.For questions regarding e reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http:/www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tol-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/053558ee0c554cc160abf4708cd2556c5d855226aa599cc49b1e4d24a2012244.jpg)

Courtney C. Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known): K101854

Device Name:

ADVIA $\textsuperscript { \textregistered }$ Chemistry GLUH_3 Reagent

Indication For Use:

For in vitro diagnostic use in the quantitative determination of glucose in human serum, plasma, urine and CSF on the ADVIA 1650 Chemistry system. Such measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and insulin overdose.

And/Or